http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

priftin is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis tb caused by mycobacterium tuberculosis 1 1 priftin is indicated for the treatment of latent tuberculosis infection ltbi caused by m tuberculosis 1 2 see limitations of use 1 1 1 2 priftin a r mycobacterium tuberculosis see dosage and administration 2 1 clinical studies 14 1 limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid inh in hiv infected patients with active pulmonary tuberculosis because of a higher rate of failure and or relapse with rifampin rif resistant organisms see warnings and precautions 5 3 clinical studies 14 1 priftin has not been studied as part of the initial phase treatment regimen in hiv infected patients with active pulmonary tuberculosis priftin is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by mycobacterium tuberculosis see clinical studies 14 2 limitations of use active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection priftin must always be used in combination with isoniazid as a 12 week once weekly regimen for the treatment of latent tuberculosis infection see dosage and administration 2 2 clinical studies 14 2 priftin in combination with isoniazid is not recommended for individuals presumed to be exposed to rifamycin resistant or isoniazid resistant m tuberculosis

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_2957 DOID_2957

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB01201 drugbank:DB01201

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-15T16:15:57.113Z

http://purl.org/np/RAKJ3r8SnB... RAKJ3r8SnB

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-15T16:15:57.113Z